About pegloticase
Pegylated uric acid–lowering enzyme
Used for
- Treats chronic gout in adults when standard treatments have not worked or are unsuitable.
- Lowers uric acid and can reduce gout flares and tophi over time.
Usual adult dose
8 mg intravenously every two weeks, with premedication and monitoring for infusion reactions.
Common side effects
- Gout flares, especially early in treatment
- Infusion reactions
- Nausea
- Bruising or throat irritation
Important warnings
- Serious allergic and infusion reactions can occur; administration requires monitoring and emergency treatment availability.
- Check uric acid before each infusion; stop if levels rise, as this can signal loss of response and reaction risk.
- Do not use with glucose-6-phosphate dehydrogenase deficiency because of risk of hemolysis and methemoglobinemia.
- Not for treating an acute gout attack; gout-flare prevention is usually needed when starting.
Pregnancy
Human pregnancy data are limited. Use only if the potential benefit justifies possible risk to the fetus.
Breastfeeding
It is unknown whether pegloticase enters human milk. Consider the mother’s treatment needs and potential infant risks.
Interactions
- Methotrexate with pegloticase may improve treatment response and reduce infusion reactions.
- Other uric-acid-lowering drugs can hide rising uric acid; avoid during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.